T. Rowe Price Associates
PLSE icon

T. Rowe Price Associates’s Pulse Biosciences PLSE Stock Holding History

T. Rowe Price Associates’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8M Buy
748,638
+733,779
+4,938% +$17.3M ﹤0.01% 1139
2026
Q1 		$321K Buy
14,859
+3,628
+32% +$67K ﹤0.01% 2654
2025
Q4 		$155K Buy
11,231
+330
+3% +$5.14K ﹤0.01% 2870
2025
Q3 		$193K Buy
10,901
+503
+5% +$7.96K ﹤0.01% 2801
2025
Q2 		$157K Buy
+10,398
New +$173K ﹤0.01% 2793
2024
Q3 		– Sell
-10,787
Closed -$121K – 3017
2024
Q2 		$121K Buy
10,787
+778
+8% +$7.33K ﹤0.01% 2721
2024
Q1 		$88K Buy
+10,009
New +$92K ﹤0.01% 2804
2022
Q3 		– Sell
-17,600
Closed -$27K – 3025
2022
Q2 		$27K Buy
17,600
+2,955
+20% +$7.43K ﹤0.01% 2917
2022
Q1 		$71K Buy
14,645
+2,000
+16% +$16.4K ﹤0.01% 2891
2021
Q4 		$187K Buy
12,645
+2,200
+21% +$43.8K ﹤0.01% 2775
2021
Q3 		$226K Sell
10,445
-2,000
-16% -$43K ﹤0.01% 2679
2021
Q2 		$204K Sell
12,445
-2,035
-14% -$38.7K ﹤0.01% 2725
2021
Q1 		$343K Sell
14,480
-3,507
-19% -$105K ﹤0.01% 2520
2020
Q4 		$429K Sell
17,987
-7,300
-29% -$116K ﹤0.01% 2307
2020
Q3 		$298K Buy
25,287
+10,300
+69% +$111K ﹤0.01% 2288
2020
Q2 		$157K Buy
14,987
+478
+3% +$4.3K ﹤0.01% 2384
2020
Q1 		$104K Hold
14,509
– – ﹤0.01% 2410
2019
Q4 		$195K Buy
14,509
+446
+3% +$6.35K ﹤0.01% 2408
2019
Q3 		$217K Buy
14,063
+88
+0.6% +$1.14K ﹤0.01% 2371
2019
Q2 		$184K Buy
13,975
+32
+0.2% +$437 ﹤0.01% 2420
2019
Q1 		$245K Buy
13,943
+400
+3% +$6.27K ﹤0.01% 2355
2018
Q4 		$155K Buy
13,543
+221
+2% +$2.67K ﹤0.01% 2447
2018
Q3 		$189K Buy
13,322
+178
+1% +$2.53K ﹤0.01% 2468
2018
Q2 		$199K Buy
+13,144
New +$222K ﹤0.01% 2462

Other funds holding PLSE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

T. Rowe Price Associates's PLSE Position: Q2 2026 in Review

T. Rowe Price Associates increased its Pulse Biosciences (PLSE) stake by 4,938% in Q2 2026, buying an estimated $17.3M and bringing the position to 748,638 shares worth $20.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

T. Rowe Price Associates first reported a position in PLSE in Q2 2018 and has held it in 24 quarters since. 105 funds tracked by Wall St. Rank hold PLSE as of Q2 2026.

  • T. Rowe Price Associates held 748,638 shares of Pulse Biosciences worth $20.8M as of Q2 2026.
  • T. Rowe Price Associates bought 733,779 Pulse Biosciences shares in Q2 2026, an estimated $17.3M.
  • Pulse Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1139 holding.
  • T. Rowe Price Associates first reported a position in Pulse Biosciences in Q2 2018 and has held it in 24 quarters since.
  • 105 funds tracked by Wall St. Rank held Pulse Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.